Related Experiment Videos
Reduced osmolarity oral rehydration solution for treating cholera
1Research and Analysis Department, Global Health Council, 1701 K Street, NW, Suite 600, Washington, DC 20006, USA. cmurphy@globalhealth.org
The Cochrane Database of Systematic Reviews
|October 21, 2004
Summary
Reduced osmolarity oral rehydration solution (ORS) may increase the risk of biochemical hyponatremia in cholera patients compared to standard ORS. However, other benefits and serious consequences were not significantly different, warranting caution in certain settings.
Area of Science:
- Infectious Diseases
- Gastroenterology
- Public Health
Background:
- Oral rehydration solution (ORS) is crucial for treating dehydration from diarrheal diseases like cholera.
- Reduced osmolarity ORS is effective for non-cholera diarrhea, but its efficacy in cholera requires investigation due to rapid electrolyte loss.
Purpose of the Study:
- To compare the safety and efficacy of reduced osmolarity ORS versus standard ORS in treating cholera-induced diarrhea.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs) comparing reduced osmolarity ORS with standard ORS.
- Searched multiple databases including Cochrane, MEDLINE, EMBASE, and LILACS up to January 2004.
- Independent review of eligibility, quality assessment, and data extraction; pooled data using relative risks and weighted mean differences.
Main Results:
- Seven trials (718 participants) evaluated glucose-based reduced osmolarity ORS.
- Biochemical hyponatremia was more common with reduced osmolarity ORS (RR 1.67), but severe hyponatremia and symptomatic outcomes were not significantly different.
- No significant difference in the need for intravenous infusion; reduced osmolarity rice-based ORS shortened diarrhea duration (WMD -16.85 hours).
Conclusions:
- Reduced osmolarity ORS is associated with biochemical hyponatremia in cholera patients compared to standard ORS.
- While other benefits are similar and serious consequences are not evident in trials, the limited patient experience necessitates caution, especially in settings with difficult patient monitoring.